WILEX AG successfully completes capital increases
- Cash capital increase of around 10% using authorised capital completed with dievini (private placement excluding shareholders’ subscription rights)
- Rights issue fully subscribed
Munich, Germany, 9 December 2015 – The Executive Management Board of WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 443,124 New Shares. Prior to the rights issue, a private placement was carried out with the main shareholder, dievini Hopp BioTech holding GmbH & Co. KG (dievini).
Private placement excluding shareholders’ subscription rights
dievini acquired all 930,560 new no par value bearer shares from the first capital measure at an issue price of EUR 1.84. Once this capital increase has been entered in the Commercial Register, this will lift the Company’s share capital by around 10%, from EUR 9,305,608.00 to EUR 10,236,168.00.
Capital increase using authorised capital with subscription rights
In addition, WILEX’s shareholders exercised their subscription and additional subscription rights for all 443,124 new no par value bearer shares at a price of EUR 1.84 per share by the end of the subscription period on 8 December 2015. Shareholders exercised subscription rights for a total of 184,419 New Shares. This meant that 258,705 New Shares were available for additional subscription by shareholders, which were allocated in full to the shareholders through their custodian banks in connection with the capital increase. Accordingly, this second capital increase will lift the Company’s share capital by EUR 443,124.00, from EUR 10,236,168.00 to EUR 10,679,292.00, once its execution has been entered in the Commercial Register.
WILEX AG plans to use the total gross issue proceeds of EUR 2.5 million from both capital increases to finance the further development of its own ADC technology (Antibody Targeted Amanitin Conjugates – ATACs). The main objective is to optimize a PSMA antibody drug conjugate as the first proprietary ATAC candidate and make this ready for early clinical development. In addition to preclinical investigations, this will entail establishing the manufacturing process for the PSMA antibody, the amanitin drug and the antibody drug conjugate at subcontractors in accordance with GMP standards.
Following the entry of the execution of both capital measures in the Commercial Register, which is scheduled to take place within the next few days, the total number of WILEX shares issued will increase to 10,679,292. The subscribed and allotted shares are expected to be delivered on 15 December 2015, but no earlier than after their admission to trading on the Regulated Market (Prime Standard). The new shares are due to be included in trading on 15 December 2015. All new shares carry dividend rights from 1 December 2015. Given this difference in dividend rights, the new shares will be traded separately under the ISIN DE000A169P97 / WKN A16 9P9 until the planned inclusion in the Company’s current listing, which will take place after the Annual General Meeting adopting resolutions regarding the 2014/2015 financial year. ODDO SEYDLER BANK AG, Frankfurt, was the sole lead manager of the capital measures.
WILEX AG is a biopharmaceutical company which discontinued all clinical development activities at its Munich site and now exercises a holding function as the Group parent. Research and development focus on the operations of its subsidiary Heidelberg Pharma GmbH in Ladenburg, which primarily advances the development of the innovative platform technology for antibody drug conjugates (ADC technology) and provides pre-clinical drug discovery and development services. WILEX has the diagnostic and therapeutic drug candidates REDECTANE® and RENCAREX®, which are available for out-licensing and further development in Phase III for external partners. WILEX is listed at the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.
Tel.: +49 (0)89-41 31 38-29
Grillparzerstr. 18, 81675 Munich, Germany
MC Services AG
Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward- looking statements to reflect future events or developments.